Jessica Sachs's most recent trade in Cogent Biosciences Inc was a trade of 82,642 Common Stock done at an average price of $38.7 . Disclosure was reported to the exchange on Dec. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.70 per share. | 26 Dec 2025 | 82,642 | 133,938 (0%) | 0% | 38.7 | 3,198,245 | Common Stock |
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 320,000 | 371,296 (1%) | 1% | 0 | Common Stock | |
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.45 per share. | 17 Dec 2025 | 154,716 | 216,580 (0%) | 0% | 39.4 | 6,103,546 | Common Stock |
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 50,000 | 51,296 (0%) | 0% | 0 | Common Stock | |
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 270,000 | 270,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 7.40 per share. | 30 Jun 2022 | 622 | 622 (0%) | 0% | 7.4 | 4,600 | Common Stock |
| Cogent Biosciences Inc | Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) |